Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Salgado

Showing results (181-190 of 277) with videos related to

Pageof 28
Sort By:
Nature Communications|October 28, 2021
Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary compositionLaura C D Pomatto-Watson, Monica Bodogai, Oye Bosompra, et al.
The Lancet. Oncology|July 12, 2017
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysisSamra Turajlic, Kevin Litchfield, Hang Xu, et al.
JAMA Oncology|November 22, 2023
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical TrialPriyanka Sharma, Shane R Stecklein, Rachel Yoder, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2022
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trialRichard D Gelber, Xin V Wang, Bernard F Cole, et al.
The Journal of Pathology|May 25, 2023
Multiscale deep learning framework captures systemic immune features in lymph nodes predictive of triple negative breast cancer outcome in large-scale studiesGregory Verghese, Mengyuan Li, Fangfang Liu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 29, 2024
Reproducible Reporting of the Collection and Evaluation of Annotations for Artificial Intelligence ModelsKatherine Elfer, Emma Gardecki, Victor Garcia, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2019
Addressing the dichotomy between individual and societal approaches to personalised medicine in oncologyRoberto Salgado, David B Solit, David L Rimm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2021
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical TrialDavid Venet, Mattia Rediti, Marion Maetens, et al.
International Journal of Oncology|December 6, 2017
p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trialAmir Sonnenblick, Roberto Salgado, Sylvain Brohée, et al.
Nature Communications|November 26, 2025
Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 studyAndreas Papagiannis, Samira Majjaj, Francois P Duhoux, et al.
Pageof 28

Showing results (181-190 of 277) with videos related to

Sort By:
Pageof 28
Nature Communications|October 28, 2021
Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary compositionLaura C D Pomatto-Watson, Monica Bodogai, Oye Bosompra, et al.
The Lancet. Oncology|July 12, 2017
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysisSamra Turajlic, Kevin Litchfield, Hang Xu, et al.
JAMA Oncology|November 22, 2023
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical TrialPriyanka Sharma, Shane R Stecklein, Rachel Yoder, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2022
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trialRichard D Gelber, Xin V Wang, Bernard F Cole, et al.
The Journal of Pathology|May 25, 2023
Multiscale deep learning framework captures systemic immune features in lymph nodes predictive of triple negative breast cancer outcome in large-scale studiesGregory Verghese, Mengyuan Li, Fangfang Liu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 29, 2024
Reproducible Reporting of the Collection and Evaluation of Annotations for Artificial Intelligence ModelsKatherine Elfer, Emma Gardecki, Victor Garcia, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2019
Addressing the dichotomy between individual and societal approaches to personalised medicine in oncologyRoberto Salgado, David B Solit, David L Rimm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2021
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical TrialDavid Venet, Mattia Rediti, Marion Maetens, et al.
International Journal of Oncology|December 6, 2017
p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trialAmir Sonnenblick, Roberto Salgado, Sylvain Brohée, et al.
Nature Communications|November 26, 2025
Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 studyAndreas Papagiannis, Samira Majjaj, Francois P Duhoux, et al.
Pageof 28